Patents by Inventor Jerome Daanen

Jerome Daanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • (Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use
    Patent number: 9682985
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: June 20, 2017
    Assignee: AbbVie Inc.
    Inventors: Jerome Daanen, David DeGoey, Jennifer M. Frost, Tammie Jinkerson, Steve Latshaw, Lei Shi
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20160304517
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson
  • (Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use
    Publication number: 20160264582
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 15, 2016
    Applicant: AbbVie Inc.
    Inventors: Jerome Daanen, David DeGoey, Jennifer M. Frost, Tammie Jinkerson, Steve Latshaw, Lei Shi
  • TRPV1 antagonists
    Patent number: 8796328
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: August 5, 2014
    Inventors: Arthur Gomtsyan, Jerome Daanen, Michael E. Kort, Philip R. Kym, Eric A. Voight, Kevin R. Woller
  • TRPV1 ANTAGONISTS
    Publication number: 20130345255
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: June 20, 2013
    Publication date: December 26, 2013
    Inventors: Arthur Gomtsyan, Jerome Daanen, Michael E. Kort, Philip R. Kym, Eric A. Voight, Kevin R. Woller
  • DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS
    Publication number: 20080097094
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: December 15, 2007
    Publication date: April 24, 2008
    Applicant: Abbott Laboratories
    Inventors: Michael Schrimpf, Karin Tietje, Richard Toupence, Jianguo Ji, Anwer Basha, William Bunnelle, Jerome Daanen, Jennifer Frost, Kevin Sippy
  • Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents
    Publication number: 20080090798
    Abstract: Heterocyclic substituted aminoazacyclic compounds of formula I Z-R3??I, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: December 12, 2007
    Publication date: April 17, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael Schrimpf, Kevin Sippy, Jerome Daanen, Keith Ryther, Jianguo Ji
  • Prodrugs of compounds that inhibit TRPV1 receptor
    Publication number: 20070099954
    Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    Type: Application
    Filed: October 27, 2006
    Publication date: May 3, 2007
    Inventors: Arthur Gomtsyan, Erol Bayburt, John Koenig, Kennan Marsh, Robert Schmidt, Chih-Hung Lee, Weili Wang, Jerome Daanen, Brian Brown
  • Antagonists of the mGlu receptor and uses thereof
    Publication number: 20060189639
    Abstract: The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.
    Type: Application
    Filed: January 17, 2006
    Publication date: August 24, 2006
    Inventors: Andrew Stewart, Guo Zheng, Teodozyj Kolasa, Pramila Bhatia, Jerome Daanen, Steven Latshaw, Xueqing Wang
  • Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
    Publication number: 20060128689
    Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
    Type: Application
    Filed: November 22, 2005
    Publication date: June 15, 2006
    Inventors: Arthur Gomtsyan, Erol Bayburt, Robert Schmidt, Chih-Hung Lee, Brian Brown, Tammie Jinkerson, John Koenig, Jerome Daanen, Steven Latshaw
  • Acetamides and benzamides that are useful in treating sexual dysfunction
    Publication number: 20060009461
    Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 12, 2006
    Inventors: Pramila Bhatia, Jerome Daanen, Ahmed Hakeem, Teodozyj Kolasa, Mark Matulenko, Kathleen Mortell, Meena Patel, Andrew Stewart, Xueqing Wang, Zhiren Xia, Henry Zhang
  • Oximes and hydrazones that are useful in treating sexual dysfunction
    Publication number: 20050176727
    Abstract: The present invention relates to oximes and hydrazones of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    Type: Application
    Filed: February 5, 2004
    Publication date: August 11, 2005
    Inventors: Teodzyj Kolasa, Meena Patel, Kathleen Mortell, Mark Matulenko, Ahmed Hakeem, Pramila Bhatia, Xueqing Wang, Jerome Daanen, Steven Latshaw, Andrew Stewart
  • Heterocyclic substituted aminoazacycles useful as central nervous system agents
    Publication number: 20050043291
    Abstract: Heterocyclic substituted aminoazacyclic compounds of formula I Z-R3 ??I, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: September 22, 2004
    Publication date: February 24, 2005
    Inventors: Michael Schrimpf, Kevin Sippy, Jerome Daanen, Keith Ryther, Jianguo Ji